Abbott India Limited, a prominent pharmaceutical company, has successfully concluded its recent postal ballot through e-voting, resulting in the approval of Mr. Darshan Gada's appointment as a Director. The company, listed under the scrip code 500488 on the BSE, made this announcement in a filing dated October 15, 2025.

Key Details of the Postal Ballot

Corporate Governance Compliance

In adherence to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has promptly disclosed the voting results. The company's commitment to transparency is evident in its immediate reporting of the outcome to the BSE and making the results available on its official website.

About the Appointment

Mr. Darshan Gada, identified by his Director Identification Number (DIN) 08174581, has been appointed to the board of Abbott India Limited. This appointment, now ratified by the shareholders, marks a significant addition to the company's leadership.

Conclusion

The successful completion of this postal ballot demonstrates Abbott India's adherence to corporate governance norms and shareholder engagement. As the pharmaceutical sector continues to play a crucial role in the global healthcare landscape, the addition of Mr. Gada to Abbott India's board may bring new perspectives to the company's strategic direction.

Investors and stakeholders can access further details about the voting results and the Scrutinizer's Report on Abbott India's official website at www.abbott.co.in .

ABB India, a key player in the industrial technology sector, has experienced a significant downturn in its stock performance over the past year, raising concerns among investors and analysts alike.

Sharp Decline in Share Price

ABB India's shares have witnessed a substantial decline, dropping over 24% year-to-date and more than 35% over the past 12 months. This performance has notably lagged behind its industry peers, including Siemens and Cummins India, both of which have shown more resilience in the market.

Valuation Correction

The stock's current valuation reflects the market's reassessment of ABB India's prospects:

This valuation adjustment stands in contrast to ABB India's competitors, which are currently trading at premiums to their historical averages.

Operational Challenges

The sharp decline in ABB India's stock price can be attributed to several operational challenges:

1. Sluggish Decision-Making: Customers are taking longer to make decisions, leading to delays in order conversions.
2. Soft Large-Ticket Business: JPMorgan anticipates a subdued performance in the large-ticket business segment for the second half of the year.
3. Margin Pressures: Analysts believe that the company has likely passed its peak margins.
4. Revenue Shortfall: Macro factors have contributed to lower-than-anticipated revenues.

Analyst Perspectives

Despite the current challenges, some analysts maintain a cautiously optimistic outlook:

• JPMorgan and Ambit Capital: Expect faster order conversion and a stronger project pipeline in the future.
• Medium-Term Growth: Potential recovery in process industries' capital expenditure could support growth.
• Brokerage Outlook:
  • 7% upside potential from current levels
  • 50% of analysts recommend a 'Buy' rating

Market Sentiment

While there's some optimism for recovery, the overall sentiment suggests that ABB India's growth momentum is expected to remain range-bound in the near term.

The company's ability to navigate these operational challenges and capitalize on potential improvements in order conversion and project pipelines will be crucial for its stock performance in the coming months. Investors and analysts will be closely monitoring ABB India's strategies to address these issues and return to a growth trajectory.